The US FDA has approved orphan drug Kynamro (mipomersen sodium) injection for the treatment of homozygous familial hypercholesterolemia (HoFH), an inherited cholesterol disorder.

Kynamro, manufactured by Genzyme, was approved as an adjunct to lipid-lowering medications and diet for patients with HoFH.

The drug was developed to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).

The FDA’s Center for Drug Evaluation and Research, metabolism and endocrinology products division deputy director Dr Eric Colman said; "Kynamro, an injection given once a week, works with other lipid-lowering medications and diet to impair the creation of the lipid particles that ultimately give rise to LDL-C."

Kynamro established its safety and efficacy profile in a trial conducted in 51 HoFH patients, demonstrating an average reduction of LDL-C by around 25%.

Common adverse reactions associated with the study drug included injection site reactions, flu-like symptoms, nausea, headache and elevations in liver enzymes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These elevations have resulted in Kynamro carrying a Boxed Warning on the serious risk of liver toxicity.

Four post marketing studies fare still required by the FDA, which include the development of a sensitive assay that binds double-stranded (ds) DNA; a study assessing antibody presence to ds-DNA in Kynamro treated patients; a long-term registry of HoFH patients to conclude Kynamro’s long-term safety and a better pharmacovigilance programme.

Image: Kynamro manufacturer Genzyme’s global headquarters in Cambridge, Massachusetts, the US. Photo: Courtesy of Tim Pierce.